```html

Xerophthalmia‑Associated Keratitis: A Comprehensive Patient Guide

Overview

Xerophthalmia‑associated keratitis is an inflammatory condition of the cornea that occurs secondary to severe dryness of the ocular surface (xerophthalmia). When the protective tear film is insufficient, the corneal epithelium becomes damaged, allowing inflammation and, in some cases, ulceration. This condition sits at the intersection of two broader disease categories:

• Xerophthalmia – marked deficiency of tears, often linked to vitamin A deficiency, Sjögren’s syndrome, or chronic environmental exposure.
• Keratitis – inflammation of the cornea caused by infection, trauma, or dryness.

Because it results from a nutritional or systemic cause, xerophthalmia‑associated keratitis is most common in:

• Children and adults living in regions with endemic vitamin A deficiency (Sub‑Saharan Africa, South‑East Asia). The World Health Organization estimates that up to 190 million preschool‑age children are at risk of vitamin A deficiency, and xerophthalmia contributes to 5‑7 % of childhood blindness globally [WHO, 2022].
• Patients with autoimmune diseases that reduce tear production (e.g., Sjögren’s syndrome, rheumatoid arthritis).
• Elderly individuals using multiple topical eye medications that destabilise the tear film.

In high‑income countries, xerophthalmia‑associated keratitis accounts for < 1 % of all keratitis cases, but it remains a leading cause of preventable corneal scarring in low‑resource settings [Mayo Clinic, 2023].

Symptoms

The clinical picture can vary from mild irritation to sight‑threatening ulceration. Common symptoms include:

• Persistent foreign‑body sensation – a gritty feeling that does not improve with blinking.
• Dryness and burning – often worse in dry, windy, or air‑conditioned environments.
• Redness (conjunctival injection) – a diffuse or localized pinkness of the eye.
• Photophobia – heightened sensitivity to light.
• Blurred or fluctuating vision – especially when the tear film breaks up.
• Tearing (reflex lacrimation) – paradoxical watery eyes due to irritation.
• Crusting or mucus at the eyelid margin – especially upon waking.
• Corneal opacity or white spot – visible on examination, indicating epithelial breakdown.
• Pain or aching – can range from mild discomfort to severe stabbing pain if an ulcer forms.
• Decreased eye comfort after contact lens wear – lenses may become intolerant more quickly.

Causes and Risk Factors

Primary Causes

1. Vitamin A deficiency – Vitamin A is essential for mucin production by conjunctival goblet cells; its lack leads to a destabilised tear film and keratinisation of the ocular surface.
2. Autoimmune exocrine gland dysfunction – Sjögren’s syndrome, systemic lupus erythematosus, and rheumatoid arthritis impair lacrimal secretion.
3. Chronic ocular surface irritation – long‑term use of preservatives (e.g., benzalkonium chloride) in eye drops, ocular prosthesis, or exposure to smoke and pollutants.
4. Medication‑induced dryness – antihistamines, isotretinoin, diuretics, and some antidepressants reduce tear production.
5. Environmental extremes – high altitude, desert climates, and indoor heating/air‑conditioning accelerate tear evaporation.

Risk Factors

• Age < 5 years (nutrition‑related xerophthalmia) or > 60 years (age‑related tear decline).
• Living in regions with limited access to vitamin‑rich foods (e.g., dairy, leafy greens).
• History of ocular surgery or trauma that damages the corneal epithelium.
• Contact lens wear, especially extended‑wear lenses without proper lubrication.
• Systemic conditions that impair immunity, such as HIV/AIDS.

Diagnosis

Accurate diagnosis involves a combination of patient history, clinical examination, and targeted tests.

Clinical Evaluation

• History taking – diet, systemic illnesses, medication use, environmental exposures.
• Slit‑lamp biomicroscopy – visualises epithelial defects, punctate staining, and corneal infiltrates.
• Tear‑film break‑up time (TBUT) – measures tear stability; <10 seconds suggests instability.
• Schirmer test – quantifies tear production; ≤5 mm/5 min is considered dry.

Laboratory and Imaging Tests

• Serum vitamin A level – low (< 0.7 µmol/L) confirms nutritional deficiency.
• Autoimmune panel – ANA, RF, anti‑SSA/SSB antibodies for Sjögren’s.
• Corneal fluorescein staining – highlights epithelial breaks; graded using the Oxford scale.
• Confocal microscopy (optional) – assesses sub‑epithelial inflammation.

Treatment Options

Management is three‑pronged: address the underlying cause, restore the tear film, and treat corneal inflammation.

1. Correcting Vitamin A Deficiency

• Oral vitamin A supplementation – WHO recommends 200,000 IU (60 mg retinol) orally on day 1, 2, and 7 for severe deficiency, followed by weekly maintenance for 2 months.
• Dietary counseling – increase intake of liver, carrots, sweet potatoes, and dark leafy greens.

2. Restoring Tear Film

• Artificial tears – preservative‑free, high‑viscosity drops (e.g., hyaluronic acid) 4–6 times daily.
• Lubricating ointments – applied at night to maintain moisture.
• Punctal plugs – occlude tear drainage, increasing residence time.
• Topical cyclosporine 0.05 % – anti‑inflammatory, stimulates natural tear production (use twice daily after a loading period).
• Lipid‑based tear supplements – for evaporative dry eye (e.g., nano‑emulsion eye drops).

3. Controlling Inflammation and Promoting Healing

• Topical corticosteroids (e.g., prednisolone acetate 1 %) – short‑course (1–2 weeks) for moderate inflammation, tapered slowly.
• Topical antibiotics – prophylactic (e.g., moxifloxacin) when epithelial defects are present to prevent secondary bacterial infection.
• Autologous serum eye drops – contain growth factors; useful for persistent epithelial defects.
• Bandage contact lens – protects the cornea while healing.
• Amniotic membrane transplantation – for refractory ulceration.

4. Lifestyle & Supportive Measures

• Humidifier use in dry indoor environments.
• Protective eyewear outdoors (wide‑brimmed hats, UV‑blocking sunglasses).
• Avoidance of smoking and exposure to second‑hand smoke.
• Regular follow‑up with an ophthalmologist (every 1–2 weeks until the epithelium stabilises).

Living with Xerophthalmia‑Associated Keratitis

Daily Management Tips

• Establish a tear‑care routine – artificial tears upon waking, mid‑day, and before bedtime.
• Warm compresses – 5 minutes twice daily to improve meibomian gland secretion.
• Gentle eyelid hygiene – use a cotton pad with diluted baby shampoo to clean margins.
• Stay hydrated – aim for ≥ 2 L of water per day.
• Monitor visual changes – keep a simple log of any new blurring, pain, or photophobia.
• Nutrition – include at least two servings of vitamin‑A‑rich foods daily; consider a multivitamin if diet is insufficient.
• Medication review – discuss with your physician whether any oral or topical drugs could be contributing to dryness.

When to Contact Your Eye Care Provider

• New or worsening pain that does not improve with lubricants.
• Increase in redness, especially if it spreads.
• New onset of watery discharge or pus.
• Sudden change in visual acuity.
• Persistent epithelial defect lasting > 48 hours despite treatment.

Prevention

Because many cases are linked to preventable nutritional deficiency or modifiable environmental factors, prevention strategies are crucial.

• Public‑health nutrition programs – fortification of staple foods (e.g., vitamin A‑fortified rice, oil) and distribution of high‑dose vitamin A supplements to at‑risk children.
• Regular eye examinations – especially for patients with autoimmune disease or chronic medication use.
• Environmental control – use humidifiers in homes and workplaces with low humidity; avoid direct airflow from fans or AC onto the face.
• Protective ocular surface – limit contact lens wear to < 8 hours/day; use lenses compatible with dry‑eye regimens.
• Education on early signs – community health workers should teach families the importance of reporting persistent eye dryness.

Complications

If left untreated, xerophthalmia‑associated keratitis can lead to serious, vision‑threatening outcomes:

• Corneal ulceration – full‑thickness epithelial loss, risk of perforation.
• Corneal scarring (nebular or macular opacity) – may cause permanent visual impairment.
• Secondary bacterial, fungal, or viral infection – especially in immunocompromised patients.
• Symblepharon – adhesion between the eyelid and globe, limiting eye movement.
• Permanent dry‑eye syndrome – requiring lifelong lubrication and monitoring.
• Vision loss – in severe cases, blindness can occur, adding to the global burden of preventable blindness.

When to Seek Emergency Care

Sources: World Health Organization (2022). Vitamin A deficiency and ocular health. Mayo Clinic (2023). Xerophthalmia and corneal disease. National Institutes of Health, Office of Dietary Supplements (2021). Vitamin A Fact Sheet. Cleveland Clinic (2024). Dry eye disease management. Peer‑reviewed articles from Ophthalmology and American Journal of Ophthalmology.

```